Viewing Study NCT06334757


Ignite Creation Date: 2025-12-24 @ 6:50 PM
Ignite Modification Date: 2026-01-01 @ 2:43 PM
Study NCT ID: NCT06334757
Status: UNKNOWN
Last Update Posted: 2024-03-28
First Post: 2024-03-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Sponsor: Henan Cancer Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module